RecruitingNot ApplicableNCT07354126

Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine

Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine Using the PedMIDAS Measuring Tool.

Sponsor

Muhammad Aamir Latif

Enrollment

44 participants

Start Date

Sep 1, 2025

Study Type

INTERVENTIONAL

Conditions

Migraine

Summary

Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.

Eligibility

Min Age: 8 YearsMax Age: 15 Years

Inclusion Criteria5

Children of any gender
Aged 8-15 years
Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria
A history of ≥4 migraine attacks/month for the preceding 3 months
With a PedMIDAS score ≥11 (moderate-to-severe impact)

Exclusion Criteria5

Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions)
Known hypersensitivity or contraindications to flunarizine or propranolol
Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma)
Non-compliance or inability to attend regular follow-ups
Participation in another clinical trial within the last 3 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFlunarizine

Patients will be receiving flunarizine beginning with 5 mg at bedtime and increasing it to 10 mg at bedtime after 1 month, over a 3-month treatment period.

DRUGPropranolol

Patient will be given propranolol beginning with 10 mg/24 hours and increase at the rate of 10 mg/week to the maximum of 60 mg/24 hour, over a 3-month treatment period.